Immunostimulatory Properties of Chemotherapy in Breast Cancer: From Immunogenic Modulation Mechanisms to Clinical Practice

被引:22
作者
Zhang, Jinguo [1 ]
Pan, Shuaikang [1 ]
Jian, Chen [1 ]
Hao, Li [1 ]
Dong, Jie [1 ]
Sun, Qingqing [1 ]
Jin, Hongwei [1 ]
Han, Xinghua [1 ]
机构
[1] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp USTC 1, Dept Med Oncol, Hefei, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 12卷
关键词
breast cancer; chemotherapy; immunotherapy; immunogenic modulation; clinic trial; PEMBROLIZUMAB PLUS CHEMOTHERAPY; CYTOTOXIC T-LYMPHOCYTES; SUPPRESSOR-CELLS; NEOADJUVANT CHEMOTHERAPY; CELLULAR-IMMUNITY; DOWN-REGULATION; DOUBLE-BLIND; OPEN-LABEL; COMBINATION; DOXORUBICIN;
D O I
10.3389/fimmu.2021.819405
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Breast cancer (BC) is the most common malignancy among females. Chemotherapy drugs remain the cornerstone of treatment of BC and undergo significant shifts over the past 100 years. The advent of immunotherapy presents promising opportunities and constitutes a significant complementary to existing therapeutic strategies for BC. Chemotherapy as a cytotoxic treatment that targets proliferation malignant cells has recently been shown as an effective immune-stimulus in multiple ways. Chemotherapeutic drugs can cause the release of damage-associated molecular patterns (DAMPs) from dying tumor cells, which result in long-lasting antitumor immunity by the key process of immunogenic cell death (ICD). Furthermore, Off-target effects of chemotherapy on immune cell subsets mainly involve activation of immune effector cells including natural killer (NK) cells, dendritic cells (DCs), and cytotoxic T cells, and depletion of immunosuppressive cells including Treg cells, M2 macrophages and myeloid-derived suppressor cells (MDSCs). Current mini-review summarized recent large clinical trials regarding the combination of chemotherapy and immunotherapy in BC and addressed the molecular mechanisms of immunostimulatory properties of chemotherapy in BC. The purpose of our work was to explore the immune-stimulating effects of chemotherapy at the molecular level based on the evidence from clinical trials, which might be a rationale for combinations of chemotherapy and immunotherapy in BC.
引用
收藏
页数:14
相关论文
共 141 条
[1]  
Adams S, 2019, ANN ONCOL, V30, P405, DOI [10.1093/annonc/mdy518, 10.1093/annonc/mdy517]
[2]   Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up A Phase 1b Clinical Trial [J].
Adams, Sylvia ;
Diamond, Jennifer R. ;
Hamilton, Erika ;
Pohlmann, Paula R. ;
Tolaney, Sara M. ;
Chang, Ching-Wei ;
Zhang, Wei ;
Iizuka, Koho ;
Foster, Paul G. ;
Molinero, Luciana ;
Funke, Roel ;
Powderly, John .
JAMA ONCOLOGY, 2019, 5 (03) :334-342
[3]   Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer [J].
Ademuyiwa, Foluso O. ;
Chen, Ina ;
Luo, Jingqin ;
Rimawi, Mothaffar F. ;
Hagemann, Ian S. ;
Fisk, Bryan ;
Jeffers, Gejae ;
Skidmore, Zachary L. ;
Basu, Anamika ;
Richters, Megan ;
Ma, Cynthia X. ;
Weilbaecher, Katherine ;
Davis, Jennifer ;
Suresh, Rama ;
Peterson, Lindsay L. ;
Bose, Ron ;
Bagegni, Nusayba ;
Rigden, Caron E. ;
Frith, Ashley ;
Rearden, Timothy P. ;
Hernandez-Aya, Leonel F. ;
Roshal, Anna ;
Clifton, Katherine ;
Opyrchal, Mateusz ;
Akintola-Ogunremi, Olaronke ;
Lee, Byung Ha ;
Ferrando-Martinez, Sara ;
Church, Sarah E. ;
Anurag, Meenakshi ;
Ellis, Matthew J. ;
Gao, Feng ;
Gillanders, William ;
Griffith, Obi L. ;
Griffith, Malachi .
BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) :187-202
[4]   Induction of immunogenic cell death of cancer cells through nanoparticle-mediated dual chemotherapy and photothermal therapy [J].
Aghda, Niloofar Heshmati ;
Abdulsahib, Shahad M. ;
Severson, Carli ;
Lara, Emilio J. ;
Hurtado, Susana Torres ;
Yildiz, Tugba ;
Castillo, Juan A. ;
Tunnell, James W. ;
Betancourt, Tania .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2020, 589
[5]  
Akram M, 2017, BIOL RES, V50
[6]   Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study [J].
Ali, H. Raza ;
Chlon, Leon ;
Pharoah, Paul D. P. ;
Markowetz, Florian ;
Caldas, Carlos .
PLOS MEDICINE, 2016, 13 (12)
[7]   Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T-Cell Transfer in Breast Cancer [J].
Alizadeh, Darya ;
Trad, Malika ;
Hanke, Neale T. ;
Larmonier, Claire B. ;
Janikashvili, Nona ;
Bonnotte, Bernard ;
Katsanis, Emmanuel ;
Larmonier, Nicolas .
CANCER RESEARCH, 2014, 74 (01) :104-118
[8]   Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells [J].
Amornsupak, Kamolporn ;
Insawang, Tonkla ;
Thuwajit, Peti ;
O-Charoenrat, Pornchai ;
Eccles, Suzanne A. ;
Thuwajit, Chanitra .
BMC CANCER, 2014, 14
[9]   Progress in adjuvant chemotherapy for breast cancer: an overview [J].
Anampa, Jesus ;
Makower, Della ;
Sparano, Joseph A. .
BMC MEDICINE, 2015, 13
[10]   Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma [J].
Aoto, Keita ;
Mimura, Kousaku ;
Okayama, Hirokazu ;
Saito, Motonobu ;
Chida, Shun ;
Noda, Masaru ;
Nakajima, Takahiro ;
Saito, Katsuharu ;
Abe, Noriko ;
Ohki, Shinji ;
Ohtake, Tohru ;
Takenoshita, Seiichi ;
Kono, Koji .
ONCOLOGY REPORTS, 2018, 39 (01) :151-159